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Serum thymus and activation regulated chemokine (TARC) levels reflect classical
Hodgkin lymphoma (cHL) disease activity and correspond with treatment response.
We compared mid-treatment interim TARC (iTARC) with interim 18F-fluo-
rodeoxyglucose positron-emission tomography (iPET) imaging to predict modified
progression-free survival (mPFS) in a group of 95 patients with cHL. High iTARC
levels were found in nine and positive iPET in 17 patients. The positive predictive
value (PPV) of iTARC for a 5-year mPFS event was 88% compared to 47% for
iPET. The negative predictive value was comparable at 86% for iTARC and 85% for
iPET. Serum iTARC levels more accurately reflect treatment response with a higher
PPV compared to iPET.
Key points
 Interim TARC levels are highly predictive of modified
progression-free survival in classical Hodgkin lymphoma
 Interim TARC levels have a better positive predictive
value than interim
18F-FDG-PET imaging for predicting
modified progression-free survival
Early response to first-line treatment determined by interim
18F-fluorodeoxyglucose (FDG) positron-emission tomogra-
phy (iPET) after one or two cycles of chemotherapy is a
strong predictor of progression-free survival (PFS) in classical
Hodgkin lymphoma (cHL) (Hutchings et al., 2014). iPET-
based treatment escalation or de-escalation resulted in
improved PFS and reduced treatment-related toxicity, respec-
tively (Radford et al., 2015; Johnson et al., 2016; Andre et al.,
2017; Borchmann et al., 2018). Nevertheless, the iPET result
does not accurately predict final outcome for all patients. In
patients with a negative iPET after two cycles of ABVD (dox-
orubicin, bleomycin, vinblastine, dacarbazin) PFS event rates
ranged from 10% up to 25% in early- and advanced-stage
patients, respectively (Johnson et al., 2016; Andre et al.,
2017). On the other hand, 25% of patients with cHL with
advanced-stage disease and a positive iPET became PET neg-
ative after completion of ABVD treatment and experienced
durable remissions (Biggi et al., 2013).
The CC-chemokine, CCL17 (also known as TARC), is a
very specific marker for cHL disease activity (van den Berg
et al., 1999; Niens et al., 2008). TARC levels are elevated in
pre-treatment blood samples in >90% of patients with cHL
and correlate with metabolic tumour volume. Serial TARC
levels reflect treatment response even after one cycle of
chemotherapy (Plattel et al., 2012; Plattel et al., 2016). In the
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present study, we compared interim TARC (iTARC) results
with simultaneous performed iPET imaging to predict modi-
fied PFS (mPFS) in patients with cHL.
The primary end-point of this study was the 5-year mPFS
rate for iTARC and iPET. Events for mPFS were defined as:
progression, relapse, start of second-line treatment for
patients not achieving a complete response (CR) after com-
pletion of treatment including radiotherapy and death due to
any cause. iTARC was considered elevated when the level
was >1000 pg/ml as previously described (Plattel et al.,
2012). Patients diagnosed with cHL from 2006 to 2017 in
our centre (n = 106) were included, based on both the avail-
ability of iPET and iTARC. A total of 10 patients (9%) were
excluded because pre-treatment TARC was not elevated and
one patient was excluded because of active atopic dermatitis,
which interferes with accurate interpretation of the TARC
measurements (Thijs et al., 2015). Data on pre- and post-
treatment TARC, but not iTARC and iPET were previously
published for 75 patients (Plattel et al., 2016).
The patients’ characteristics of the remaining 95 patients
are listed in Table I. The median (range) follow-up for the
entire cohort was 58 (7–130) months. In all, 54 (57%)
patients had early- and 41 (43%) advanced-stage disease.
Most patients were treated according to European Organisa-
tion for Research and Treatment of Cancer (EORTC) proto-
cols, active during the study period (Carde et al., 2016;
Andre et al., 2017). Early-stage patients were generally treated
with three to four cycles of ABVD combined with involved-
node radiotherapy in 70% of patients. Advanced-stage
patients mainly received six–eight cycles of ABVD (59%) or
(esc)BEACOPP (bleomycin, etoposide, adriamycin (doxoru-
bicin), cyclophosphamide, vincristine, procarbazine, pred-
nisone) (30%) combined with radiotherapy on remaining
FDG-PET-positive lesions after completion of chemotherapy
(7%). Response was re-defined according to the Lugano clas-
sification (Cheson et al., 2014). Interim response evaluation
with iTARC and iPET was performed at the same time-
point, that is, after two cycles of chemotherapy in early-stage
patients and after two or three cycles of chemotherapy in
advanced-stage patients. TARC was also measured after the
first cycle of chemotherapy in most patients, but compar-
isons between iTARC and iPET were only performed on
simultaneous evaluations after two or three cycles. No treat-
ment adjustments were made based on iTARC or iPET
results, except for omission of radiotherapy in 25% of early-
stage patients with a negative iPET, which is in accordance
with the experimental arm of the EORTC trial H10 (Andre
et al., 2017).
At the mid-treatment time-point, iPET was positive
(Deauville Score ≥4) in 17/95 (18%) and iTARC was elevated
in nine of 95 (8%) patients (Figure S1). Concordance
between iTARC and iPET was 87%. Both negative iPET and
normal iTARC levels (double negative) were observed in 76
patients, both positive (double positive) in seven and dis-
crepant results were found in 12 patients. Of the 76 double-
negative patients, 71 patients remained in remission, three
patients were progressive at end of treatment (both TARC
and PET became positive again at end-treatment) and two
experienced a relapse >1 year after completion of first-line
treatment with again elevated TARC and positive FDG-PET
at time of relapse. Six out of seven double-positive patients
were refractory to first-line treatment and one patient with a
massive pre-treatment tumour load and an extremely high
TARC level became both FDG-PET and TARC negative at
end of treatment and remained in remission. From the 12
patients with discrepant results at mid-treatment, two
patients had positive iTARC and negative iPET: one patient
remained TARC positive at end of treatment, became FDG-
PET positive and was considered progressive and the other
remained TARC positive and PET negative but experienced
early relapse. The other 10 patients with discrepant results
had a low iTARC and a positive iPET: seven of these 10
became FDG-PET negative at end of treatment, remained
TARC negative and did not experience relapse, one remained
TARC negative and PET positive and was considered respon-
sive based on a negative re-biopsy, one became TARC posi-
tive at end of treatment and was considered refractory, and
one remained TARC negative and proceeded to salvage treat-
ment without re-biopsy. In conclusion, eight out of nine
iTARC-positive patients were either primary refractory or
had an early relapse. Of the 86 iTARC-negative patients, 79
obtained a persistent complete remission. In contrast, nine of
17 iPET-positive patients obtained a durable complete remis-
sion, seven patients were refractory, and one patient received
second-line treatment without re-biopsy.
All patients with a CR after completion of treatment had
a strong decrease in TARC levels, which was already evident
after one cycle of chemotherapy (Fig 1A). Both at mid-treat-
ment and end of treatment high TARC levels were associated
with a Deauville Score of 5 (Fig 1B,C). Concordance between
TARC and FDG-PET was 96% at end of treatment (Table I).
The 5-year mPFS was 81% for the entire cohort, 84% for
early-stage and 74% for advanced-stage patients. The iPET-
positive patients had significantly reduced mPFS at 5 years
compared to the iPET-negative patients (53% vs. 85% at 5-
years, P < 0.001; Fig 1D). In contrast, mPFS at 5 years for
patients with elevated iTARC was 11% compared to 86% for
patients with normal iTARC levels (P < 0.001, Fig 1E). In a
combined model with iPET and iTARC, patients with nor-
mal iTARC levels generally had a favourable mPFS, whereas
patients with elevated iTARC had very poor outcomes, irre-
spective of iPET results (Fig 1F). Consistent with this only
iTARC remained predictive for mPFS in multivariate analy-
sis, including both iPET and iTARC using the Cox propor-
tional hazard method (hazard ratio for elevated iTARC 131,
95% confidence interval 35–494; P < 0.001).
This is the first study demonstrating that the blood-based
biomarker TARC can improve interim response evaluation in
cHL. We and others already found a strong correlation
between early TARC decrease and final favourable outcome
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Table I. Patients’ characteristics according to iTARC.
Characteristic
Total
(N = 95) iTARC <1000 pg/ml (n = 86)
iTARC ≥1000 pg/ml
(n = 9)
Age, years, median (range) 32 (18–82) 31 (18–82) 49 (25–79)
Male, n (%) or n/N 42 (44) 37 (43) 5/9
Stage I/II, n (%) or n/N 54 (57) 51 (59) 3/9
Follow-up, months, median (range) 58 (7–130) 62 (14–130) 19 (7–82)
mPFS event, n (%) or n/N 18 (19) 10 (12) 8/9
iPET, n (%) or n/N
Negative (DS 1–3) 78 (82) 76 (88) 2/9
Positive (DS 4–5) 17 (18) 10 (12) 7/9
End of treatment TARC, n (%) or n/N
<1000 pg/ml 84 (88) 82 (95) 2/9
≥1000 pg/ml 11 (12) 4 (5) 7/9
End of treatment FDG-PET, n (%) or n/N
Negative 82 (86) 79 (92) 3/9
Positive 13 (14) 7 (8) 6/9
End of treatment response, n (%) or n/N
Complete response 84 (88) 81 (94) 3/9
Partial response 6 (6) 2 (2) 4/9
Progressive disease 5 (5) 3 (3) 2/9
TARC, thymus and activation regulated chemokine; mPFS, modified progression-free survival; FDG-PET, fluorodeoxyglucose positron-emission
tomography; DS, Deauville Score.
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Fig 1. TARC and FDG-PET results during and after treatment. (A) Dynamics of TARC before treatment, after one cycle of chemotherapy, at
mid-treatment and at end-treatment. TARC levels were analysed using a sandwich enzyme-linked immunosorbent assay (R&D systems). The cut-
off for TARC positivity at the mid-treatment time point was 1000 pg/ml as previously defined (Plattel et al., 2012). Patients achieving a complete
response without experiencing a relapse are displayed in black. Patients with refractory disease or patients experiencing a relapse are displayed in
red. (B) TARC levels at mid-treatment compared to mid-treatment FDG-PET Deauville score. FDG-PET images were reconstructed according to
the European Association of Nuclear Medicine criteria. All FDG-PET scans were re-analysed and visually re-assessed according to the Lugano
classification, which incorporates the Deauville 5-point scale. A Deauville Score ≥4 was considered FDG-PET positive. (C) TARC levels at end-
treatment compared to end-treatment FDG-PET Deauville Score. (D) Modified progression-free survival (mPFS, see methods for definition)
according to mid-treatment FDG-PET result. FDG-PET negativity was defined as Deauville Score ≤3 and FDG-PET positivity was defined as
Deauville Score of 4 or 5. (E) mPFS according to mid-treatment TARC result. TARC negativity was defined as TARC below the cut-off of
1000 pg/ml. (F) mPFS according to combined FDG-PET and TARC result. iTARC negativity generally correlated with favourable outcome,
whereas iTARC positivity correlated with adverse outcome irrespective of the iPET result. Survival analyses were performed using the method of
Kaplan and Meier and the log-rank test was used to assess significance.
Short Report
ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd 3
(Plattel et al., 2012; Guidetti et al., 2017; Hsi et al., 2019).
Guidetti et al. confirmed early TARC decrease as a predictor
for iPET negativity. In their study, normalisation of TARC
levels after one cycle of chemotherapy highly corresponded
with a negative PET after two cycles of ABVD treatment
(Guidetti et al., 2017). However, the positive predictive value
(PPV) of TARC after one cycle for PET positivity after two
cycles was rather limited. This might be due to the high rate
of false positive iPET scans. Also, the PPV of elevated TARC
for PFS was lower compared to our present study, likely due
to the combination of a lower threshold for TARC positivity,
different timing of TARC measurement and the uniform
treatment escalation based on a positive FDG-PET, which
might have biased their study (Guidetti et al., 2017). The
exclusion of patients with treatment escalation based on iPET
allowed us to directly compare prognostic value of both iPET
and iTARC. Very recently, Hsi et al. analysed among others
serial TARC levels in the prospective Southwest Oncology
Group (SWOG) S0816 trial and found that end of treatment
TARC could aid in prognostication independent of PET
imaging (Hsi et al., 2019). We found a high concordance
between TARC and FDG-PET, especially at the end of treat-
ment time-point. iTARC-based response evaluation showed
an improved PPV for 5-year mPFS (from 47% to 89%) and
similar negative predictive value (88%) as compared to iPET
imaging, despite a possible bias in the use of FDG-PET for
final response assessment. Similar to the study by Hsi et al.,
end of treatment TARC elevation was highly predictive for
mPFS: all 11 patients with elevated end of treatment TARC
levels were either refractory or experienced early relapse. The
higher PPV of TARC compared to PET can be explained by
the high specificity of elevated TARC for tumour activity, as
TARC is specifically produced and excreted by Hodgkin
Reed–Sternberg cells. Serum TARC-based response evaluation
is non-invasive and cheap, allowing response adapted therapy
in cHL worldwide. A limitation of the use of TARC as a bio-
marker is that it is not applicable in the 10% of patients who
do not have elevated pre-treatment TARC. Although results
of our present study are very promising, our modest cohort
size warrants validation in a larger cohort.
In conclusion, elevated iTARC levels determined at mid-
treatment are highly predictive for inferior mPFS with a
higher PPV compared to iPET. As TARC is elevated at base-
line in about 90% of patients with cHL, iTARC measure-
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Additional supporting information may be found online in
the Supporting Information section at the end of the article.
Figure S1. Outcome of patients with interim PET and
interim TARC results.
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